View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job


CMC Development for Biologics: Purification, Formulation, Analytical Characterization, Production Systems, Regulatory and Product Development

Speakers: Judy Chou (Bayer); Michelle Frazier (Soigneur Regulatory Consulting); Rafi Mohammad (Bayer); David R. Dodds (Rondaxe); Shuang Chen (NGM Biopharmaceuticals); Guifeng Jiang (Boerhinger Ingelheim); Benson Gikanga (Genentech); Peter Soler (BMS)
Organizers: Jim Zhang (Menlo Therapeutics), Rafi Mohammad (Bayer), Minli Xie (Myovant)
Date: 2019-05-06
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Abzena; Waters Corp.
Vendor show vendors registered to date: (13)Absorption Systems; Analytical Lab Group; Applied StemCell; Aragen Bioscience; Charles River; Intertek; MabPlex USA, Inc.; MilliporeSigma [Sigma-Aldrich,Inc.]; MRIGlobal; Pacific BioLabs; PHC former Panasonic Healthcare; Pion Inc.; PPD
Registration deadline:2019-05-01  (it will close sooner if the seating cap is reached)

About the Topic

Biologics today are widely used as targeted therapies and provide numerous advantages over conventional small molecule approaches.  However, the processes and products are much less understood than their small molecule counterparts. Biologics medicines are manufactured via complex processes and have many potential sources of heterogeneity, often impacting function. 

This workshop provides an overview of CMC (Chemistry, Manufacturing and Controls) development of biologicals, including the technologies of biological production via cell culture and fermentation, purification processing, drug product and packaging and analytical control systems.  The lifecycle of development from product definition, preclinical, clinical and commercial stages will be covered.  Approaches and challenges for processing and analytical development will be addressed.  Case studies will be discussed to illustrate approaches to develop successful manufacturing processes and effective analytical control strategies. 

This workshop will benefit scientists, analysts and BD associates, research associates, managers, directors, regulatory affairs, quality control, quality assurance, and device and process engineers currently working in the pharmaceutical and biotechnology industry who want to improve their understanding of the best practices in CMC development of biologicals.  This workshop is also useful for non-pharma scientists who seek better technical understanding of processes, challenges and opportunities in the industry.

The following key topics will be discussed.

  • Purification process of biologics
  • Biologics drug product development including formulation and device development, compatibility and automation
  • Analytical characterization of biologics
  • Regulatory aspects of biologics development
  • Production systems of biologics


Workshop Agenda

8:45-8:55           Welcome and overview - Shichang Miao, Jim Zhang, Rafi Mohammad

8:55-9:40           1. Overall CMC strategy - Judy Chou

9:40-10:25         2. Regulatory process - Michelle Frazier

10:25-10:35       Major Sponsor Presentation - Abzena

10:35-10:55       Break & Vendor Show

10:55-11:40       3. Biological Drug Product Compatibility - Rafi Mohammad

11:40-12:25       4. Production system - David R. Dodds

12:25-13:25       Lunch

13:25-14:10       5. Down Stream Processing: Principles, Development, and Implementation of Manufacturing Processes - Shuang Chen

14:10-14:55       6. Analytical Characterization for Monoclonal Antibody - Guifeng Jiang

14:55-15:05       Major Sponsor Presentation -  Waters

15:05-15:25       Break & Vendor Show

15:25-16:10       7. Process Development : Impact of Processing Equipment Design on Product Quality of Biologics: A case Study - Benson Gikanga

16:10-16:55       8. Formulation Development: Leveraging the Laboratory Automation and High-Throughput Screening - Peter Soler

16:55-17:25       Panel Discussion

2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/14/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad